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Using the Taiwan nationwide laboratory-confirmed
severe acute respiratory syndrome (SARS) database, we
analyzed neutralizing antibody in relation to clinical out-
comes. With a linear mixed model, neutralizing antibody
titer was shown to peak between week 5 and week 8 after
onset and to decline thereafter, with a half-life of 6.4 weeks.
Patients with a longer illness showed a lower neutralizing
antibody response than patients with a shorter illness dura-
tion (p = 0.008). When early responders were compared
with most patients, who seroconverted on and after week 3
of illness, the small proportion (17.4%) of early responders
(antibody detectable within 2 weeks) had a higher death
rate (29.6% vs. 7.8%) (Fisher exact test, p = 0.004), had a
shorter survival time of <2 weeks (Fisher exact test, p =
0.013), and were more likely to be > 60 years of age (Fisher
exact test, p = 0.01). Our findings have implications for
understanding the pathogenesis of SARS and for SARS
vaccine research and development. 
S
evere acute respiratory syndrome (SARS) is a newly
emerged infectious disease. Its etiologic agent is a
novel coronavirus (SARS-CoV) (1,2), which can readily
infect a variety of wild and laboratory animals without
causing apparent clinical symptoms (3,4), making the exis-
tence of an animal reservoir possible. In humans, SARS
appears with a wide clinical spectrum, ranging from self-
limited pneumonia to acute respiratory distress syndrome
(ARDS) and death (5,6). Anecdotally, asymptomatic infec-
tion has also been reported (7).
Autopsies of SARS patients have found the virus to be
widespread throughout a variety of tissues and organs (8).
During the acute phase, the virus is found in the excreta of
infected persons (9,10) and is thought to be transmitted by
direct contact, droplets, or contaminated environmental
surfaces. Infection can be prevented largely by good hand
hygiene, although some healthcare settings and communi-
ties may be prone to the aerosolization of contaminated
human excreta, and in these cases, precautionary measures
should be instigated accordingly (11,12). The chain of
human transmission has been successfully interrupted by
public health measures, but potential reintroduction of the
virus from an unidentified natural reservoir remains a con-
cern. A wealth of clinical and epidemiologic observations
have emerged and contributed to the successful control of
the SARS epidemic (see Peiris et al. [13] for a review).
However, information on immunity and pathogenesis is
insufficient to provide a comprehensive basis for specific
drug or vaccine design. Nor have animal pathogenic mod-
els been established that adequately resemble the patho-
genesis of SARS in humans. Without a good experimental
model to study the biologic basis for human disease, the
observational data collected from reported SARS case-
patients, along with the associated laboratory diagnostic
tests, will continue to provide essential leads in controlling
a possible reemergence of SARS. To gain a better insight
into the humoral responses in the context of epidemiolog-
ic and clinical settings, we analyzed the neutralizing anti-
body data, along with a variety of epidemiologic elements
in the database. 
Material and Methods
This retrospective analysis is based on Taiwan’s nation-
wide database on SARS cases reported from March to July
2003 to the Center for Disease Control in Taiwan (Taiwan-
CDC). The criteria for reporting SARS patients evolved
over time but were principally adopted from the World
Health Organization, and the total reported probable SARS
patients in Taiwan were 665. 
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The epidemiologic database contains basic demograph-
ic information (age, sex, city/county of residence); symp-
toms at onset; date of onset of first symptoms; date of
diagnosis; dates of hospitalization, discharge, or death;
results of all epidemic investigations on contact tracing;
travel history; and results of laboratory tests of reverse
transcription–polymerase chain reaction (RT-PCR) on
SARS-CoV and other pathogens in the differential diagno-
sis of atypical pneumonia. The analysis of epidemiologic
data has been reported previously (14,15). The detailed
laboratory data taken from molecular and serologic tests of
SARS-CoV infection were compiled in a separate file that
could be linked to the epidemiologic data. The concor-
dance and discordance between various serologic tests and
molecular diagnostic methods of SARS have also been
reported previously (9). The serum neutralizing antibody
was measured by microtiter assay and by enzyme-linked
immunosorbent assay (ELISA) (Centers for Disease
Control and Prevention, Atlanta, GA, USA) as described
(9). 
Severity of Illness
Hospitalization served the dual purposes of isolating
patients and providing health care; therefore, criteria for
discharging patients, i.e., being afebrile for 5 days and
clinical improvement, were stringently adhered to by the
clinicians as a part of public health practice. Since no
antiviral drug was known to effectively shorten the clinical
course of SARS, the duration of illness, defined as the
number of days between onset of fever and time of dis-
charge from the hospital, can be assumed to reflect the
clinical severity of SARS manifested by the patient. To
validate the consistency of the interhospital practices in
patient care in relation to the severity of patients, we col-
lected and analyzed anonymous and computerized clinical
data, focusing on oxygen supplementation and respiratory
therapy, on a sample of SARS patients from 3 hospitals
that represented 3 healthcare accreditation levels in
Taiwan: a major medical center (National Taiwan
University Hospital), a regional teaching hospital (Taipei
Mackay Memorial Hospital), and a district hospital (Taipei
Hospital). Regardless of hospital, duration of illness corre-
lated highly with the supplementation of oxygen, which is
a good surrogate for the level of pulmonary dysfunction (p
for trend <0.001) (Table 1). Thus, in our analysis, duration
of illness was used as a surrogate for clinical severity
among the surviving SARS patients, and death rate was
also used as severity index. For the convenience of discus-
sion, a duration of illness <2 weeks was considered mild,
2–4 weeks as intermediate, and >4 weeks as severe. Afatal
case, regardless of the length of survival, was considered
severe. Our data corroborate the report that SARS patients
with a severe clinical course mainly had a slower and pro-
longed recovery (16).
Statistical Analysis 
Data were analyzed with SAS software (Version 8, SAS
Institute Inc, Cary, NC, USA). Differences in frequencies
or proportions were tested using a χ2 test and by risk ratios.
The continuous variables, i.e., age distribution or titers of
neutralizing antibody, were compared by using the
Wilcoxon rank-sum nonparametric method. Multivariate
logistic regression (17) was used to analyze factors that
can affect seropositivity, including demographic informa-
tion, source of infection, and duration of illness. To adjust
the time effects and other covariates of interest, the rela-
tionship between antibody titer, based on logarithmic
transformation of base 2 (serum dilution) and other poten-
tial factors, i.e., age, sex, infection source, and duration of
illness, was quantified by linear mixed models (18), which
took into account the correlation between repeated meas-
urements of each study participants.
Results
Participants
Specimens from all patients with probable SARS in
Taiwan were serologically tested for case confirmation,
with a particular focus on the convalescent-phase serum
specimens, as previously reported (9). Positive neutraliz-
ing antibody results, which correlated well with those of
ELISA (Table 2), were used as the standard assay for case
confirmation. Thus, 347 of 665 reported probable SARS
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patients whose diagnoses were based on serologic testing
alone, 121 whose results were positive by both tests, and
100 patients whose diagnoses were based on the RT-PCR
alone. Of these 100 diagnoses based on RT-PCR alone, 32
had convalescent-phase serum specimens that tested nega-
tive, and 68 did not have appropriate convalescent-phase
serum specimens for antibody testing because of death,
loss to follow-up, or inappropriate timing of serum collec-
tion (Table 3).
Seronegative Results
We examined whether the seronegative results of the 32
patients were false-positive instances of virus detection by
RT-PCR, most commonly caused by laboratory error or
contamination. Cross-contamination in the laboratory
should occur without any correlation with the patients’
demographic or clinical parameters. The seronegative rate
(19.1%, 18/94) was significantly higher in men than in
women (7.5%, 14/185) (Mantel-Haenszel test, p = 0.004),
but the effect of age was not statistically significant (p =
0.07 in men, χ2 test) (Figure 1). Based on the transmission
risk of known or unknown sources, patients whose sources
could not be ascertained, i.e., had no apparent history of
having contact with SARS patients, were significantly
more likely to be seronegative (45.1%, 23/51) than those
with known sources of infection (3.7%, 8/212) (χ2,
p<10–7) (Table 4). Patients with a shorter duration of ill-
ness were more likely to be seronegative; 14 (30.4%) of 46
patients with a duration of illness <14 days, 8 (9.8%) of 81
patients with illness durations of 15 and 21 days, 5 (7.8%)
of 64 patients for those with 22 and 28 days, and none of
those who survived for >28 days (χ2 for trend = 20.5, p =
0.00001). A logistic regression model confirmed that
patients with a known source of infection (odds ratio [OR]
= 15.6, p<0.0001) and a longer duration of illness (OR =
1.08 for each additional day of illness, p = 0.004) were
more likely to possess a detectable level of neutralizing
antibody than those with no discernible infection source
and shorter duration of illness (Table 5).
Antibody and Duration of Illness 
The total number of serum specimens collected from
each patient ranged from 1 to 4, including >1 convales-
cent-phase serum sample collected after week 4. Of the
247 seropositive SARS patients, 217 (87.8%) of the
patients were seropositive by week 3; 27 (17.4%) of 155
patients who were seropositive within the first 2 weeks of
illness and are called early responders hereafter. On rare
occasions (1.21%, 3/247), seroconversion occurred after
week 6 of symptoms onset. 
Because of the differences in the distribution of age and
sex among patient groups and the differences in the num-
ber and timing of specimens collected for antibody meas-
urement, we used regression-based modeling approach to
examine these factors simultaneously and tried to analyze
the relationship between their potential interactions and
antibody titers (Table 5, Figure 2A). This model was based
on the neutralizing antibody titer of the 312 convalescent-
phase serum assays, representing 194 patients who had had
1 convalescent-phase serum sample collected between
weeks 3 to 12 after onset of fever, 41 patients who had 2
convalescent-phase samples, and 12 patients who had 3.
The number of serum specimens collected ranged from 21
to 43 per week from week 4 of illness through week 12.
The model suggested that neutralizing antibody rose and
diminished during the follow-up period between weeks 3
and 13 after onset of illness (p = 0.026 for linear term and
p = 0.042 for quadratic term); the estimated half life was
≈6.4 weeks. Patients with a more protracted clinical course
tended to have a higher antibody titer than patients with a
shorter clinical course (p = 0.008). Antibody in patients
with more severe clinical courses tended to decay at a
faster rate than in patients with shorter clinical course (the
interaction between duration of illness and time of serum
collection, p = 0.037). This pattern of decay followed a
half-life of ≈6.4 weeks after reaching the peak, which
occurred between weeks 5 and 8 after infection (Figure
2B). The time that the blood was collected for each patient
was examined, and an equally dispersed pattern of blood
collection was found in all clinical groups (Figure 3). 
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phase specimen collected after 6 weeks, 16 (31.2%) of 53
showed a 4-fold (2 dilution) drop by week 12 postinfec-
tion. Three patients had a negative seroconversion during
the same period. Conversely, a measurable neutralizing
antibody persisted in 12 (85.7%) of 14 patients who had
been followed up between weeks 13 and 16. To better
examine the dynamics of the antibody profile, cross-sec-
tional views of Figure 2A were extracted (Figure 2B). The
model suggested that antibody response was higher and
occurred earlier in patients with a more severe clinical
course than in those with a shorter clinical course.
Early Responders and Deaths
In the model, patients with a more severe clinical
course had earlier and higher antibody responses; we then
examined the death rate of the early responders (Table 6).
These early responders had a significantly higher mortali-
ty rate (29.6% vs. 7.8%) than others who did not undergo
seroconversion until week 3 of illness or later (p = 0.004,
χ2 test). These early responders also tended to die early
during the acute phase: 6 of 8 died during the first 2 weeks
of illness, and the other 2 died on days 15 and 17 of illness,
respectively (Fisher exact test, p = 0.028). Of the 10
patients who died and who seroconverted after the second
week of symptom onset, only one died during the first 2
weeks of illness (Wilcoxon rank sum, p = 0.007). Among
the 27 early seroresponders, the antibody titer of those who
died (n = 8) (median titer = 48) was not significantly high-
er than that of those who survived (median titer = 32)
(Wilcoxon rank sum, p = 0.79). However, the early serore-
sponders were significantly older (mean age 43.7 years)
than the 128 case-patients who seroconverted after week 2
of illness (mean age 37.3 years) (Wilcoxon rank sum, p =
0.028); i.e., older patients were more likely to be early
responders, 60% of patients >60 years of age versus 16.3%
of patients <60 years (Fisher exact test, p = 0.004).
Discussion
Neutralizing antibody plays an integral role in immuno-
protection from viral diseases, and serologic tests are
important to their diagnosis. This report relates SARS neu-
tralizing antibody profiles to clinical outcomes. The lack
of a readily available, well-characterized diagnostic assay
that could be used as a standard and the additional lack of
a well-established typical clinical description that encom-
passes all clinical syndromes are intrinsic difficulties of
working with a new infectious disease. Therefore, analysis
of the interrelation between clinical, epidemiologic, and
laboratory data might provide further insight into these ele-
ments. Results of our analysis, although they passed a cer-
tain level of statistical scrutiny, should be interpreted with
caution.
Antibody Titer and Seronegativity
The 32 seronegative SARS patients whose diagnoses
were based on positive RT-PCR results of nasopharyngeal
swab specimens warrant further discussion concerning
whether they were indeed SARS patients or were merely
misdiagnosed by the false-positive RT-PCR of SARS-CoV.
The false-positive RT-PCR is most commonly due to
cross-contamination, which pertains to the nature and
quality of a laboratory procedure and should be independ-
ent of patient’s profile. However, we found that seronega-
tive patients were more likely to have a short duration of
illness and no clear source of infection. Lack of specifici-
ty of the test is another reason for having a false-positive
RT-PCR, but none of the commercial tests we used have
been reported to have nonspecific cross-reactivity with
other known pathogens. Furthermore, after May 1, SARS
diagnosis required positive results of >2 specimens col-
lected at different time or from different sites, or tested by
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Figure 1. Positive rate of severe acute respiratory syndrome–
associated coronavirus titer by sex and age.>1 RT-PCR method (Centers for Disease Control and
Prevention, Atlanta, GA, USA; Roche Diagnostics GmbH,
Mannheim, Germany; Artus GmbH, Hamburg, Germany)
if only 1 specimen was available. Therefore, a specimen
that yields false-positive results with 2 different test meth-
ods is deemed unlikely.
Alternatively, these 32 patients were indeed SARS
patients, but the negative neutralizing antibody reading was
due to patent’s low antibody level in combination with the
low sensitivity of the antibody test. The sensitivity of our
neutralizing assay is comparable to that of ELISA (9), but
the possibility that our assay had a low sensitivity remains
because the neutralizing antibody test is based on the read-
ing of a complete inhibition of cytopathic effect. Thus the
absolute titer is expected to be lower than the results, based
on reading of 50% inhibition. The neutralizing antibody of
SARS patients has been reported in only 1 other study, in
which a pseudovirus containing the S protein of SARS-
CoV was used; antibody titers were found to be low (19). A
low antibody response may be associated with a primary
infection of SARS-CoV, as seen with primary infection of
respiratory syncytial virus (RSV) (20), and infection
through the respiratory tract was shown to stimulate a less
vigorous immune response than infection by an invasive
intravenous rejection of RSV (21). Furthermore, a robust
humoral immune response requires antigen in sufficient
doses through a proper route; this fact has been demonstrat-
ed in vaccine studies, including research on several live
vaccines (22−24). The lack of detectable antibody among
patients without history of contact with a known SARS
RESEARCH
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Figure 2. A) Perspective surfaces of neutral-
izing antibody titer (dilution) based on the fit-
ted linear mixed model in Table 5. The
median age was 36 years for men (left
panel) and for women (right panel). B)
Cross-sectional curves of neutralizing anti-
body titer (dilution) extracted from panel A
with duration of illness set at 10, 17, 24, and
31 days, respectively, for men (left panel)
and women (right panel); the vertical lines
mark peak titer times. 
A
Bpatient might be associated with a low inoculum of the
virus because of incidental exposures, in contrast to patients
who acquired SARS in hospitals under circumstances
assumed to have a high virus density. When systematically
screened during the SARS outbreak, some healthcare work-
ers and public health personnel who had a history of direct
contact with patients were shown to harbor nasopharyngeal
SARS-CoV. Subsequently, however, they did not show
seroconversion (Y.-T. Lu et al., unpub. data), which raises
the possibility of asymptomatic mucosal epithelial colo-
nization by SARS-CoV. Our seronegative patients with
mild symptoms might fit into the spectrum between the
seronegative asymptomatic colonizers and the severe SARS
patients with high neutralizing antibody response. All con-
siderations appear to favor the possibility that seronegative
patients indeed had acquired SARS. Since the natural reser-
voir of SARS-CoV has not been clearly identified, and rein-
troduction of SARS-CoV to humans is possible, the short
duration of having detectable antibody should be consid-
ered when a vaccine against SARS-CoV is developed.
Severity and Pathogenesis 
The clinical course of SARS patients with severe infec-
tion is described as follows: pulmonary functions worsen
during week 2 of illness (5,25−27), while the virus load in
the airway decreases (5), and patients with mild disease
would begin to stabilize clinically. Those in whom ARDS
later develops usually show pulmonary decompensation
during week 2. Severity was intensified by a slower and
prolonged recovery with complications of pulmonary
fibrosis occurring in week 3 in some patients (16). Results
of a high-resolution computed tomographic scan in follow-
up of SARS patients corroborates this observation by
showing a high correlation between bilateral fibrotic lung
changes and clinical severity (28). Findings of these stud-
ies, in conjunction with clinical study on cytokines during
the acute phase (29−31), suggest that activation of Th1
cell–mediated immunity and a hyperinnate inflammatory
response, rather than direct damages from uncontrolled
virus growth, are responsible for the pathogenic process in
severe infection (5). In previous vaccine studies, immu-
nization conditions that could induce a stronger activation
of Th1 response would concurrently result in a higher anti-
body response (24,32). Thus, the high antibody response
and a strong cell-mediated Th1 response may reasonably
be understood as concurrent events, and the latter may be
causally related to a severe clinical course of SARS.
Neutralizing antibody is unlikely to be causally related to
the pathogenesis of SARS because treating SARS patients
with convalescent-phase serum collected from patients
who had recovered from SARS showed no adverse effect
and probably had beneficial effects (33). Thus, for all the
reasons stated above, our finding that high neutralizing
antibody correlating with clinical severity should not be
interpreted to mean that neutralizing antibody is harmful. 
Death Rate and Early Responders
Having a detectable neutralizing antibody during the
first 2 weeks of illness, in our analysis, coincides with a
high and an early SARS mortality rate. The basis for early
antibody response is not apparent, but 1 possibility is the
priming effect of a previous non–SARS-CoV infection.
Indeed, antibody against SARS-CoV has been shown to
cross-react with human coronavirus 229E (2). The finding
that early responders are older than other SARS patients is
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Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 11, November 2005 1735
Figure 3. Scatterplot of antibody titers of the 247 seropositive
study participants (titers of the same participant measured at dif-
ferent times are connected); superimposed is the fitted mean
curve (in red) of log2 (antibody titer) between weeks 3 and 13
postinfection based on the linear mixed model by severity (dura-
tion of illness) and sex at the median age of 36 years. Each dot
represents >1 titer; no distinction is made between single values
and those with >1 value.in agreement with the priming effect since cumulative
infection rate increases with increasing age. The priming
effect of a previous viral infection can induce cross-reactive
but nonneutralizing antibody, as well as neutralizing anti-
body to SARS. Furthermore, the nonneutralizing antibodies
are known to facilitate viral infection, termed antibody-
dependent enhancement (ADE), which is the pathogenic
basis of feline infectious peritonitis virus (FIPV, a type II
coronavirus), dengue hemorrhagic fever, and other viruses
(34–36,37). In the case of FIPV, ADE can occur even with
neutralizing antibody (38). However, this type of ADE
resulted directly from neutralizing antibody is unlikely to
occur with SARS-CoV infection because a number of
SARS patients have been treated with convalescent-phase
serum of SARS patients and show no adverse effect (33). 
The hypothesis that the early responders may have
experienced a priming effect could be verified by demon-
strating that a significantly higher proportion of early
responders than other SARS patients possess antibody
against non-SARS coronavirus during the acute phase.
Early death occurring within the first 2 weeks of illness is
also associated with high nasopharyngeal virus load
among a subset of SARS patients with information on
nasopharyngeal virus load (J.-Y. Yang et al., unpub. data).
Unfortunately, the number of early responders for whom
information on virus load was available was too few to
yield a meaningful statistical analysis on whether high
virus load is correlated with an early humoral response.
While antibody induced by a variety of SARS-CoV anti-
gen preparations protects against SARS-CoV infection in
mice and ferrets (39,40), these animals do not develop
clinical symptoms resembling that of SARS-CoV infection
in humans and thus are not models of pathogenesis. Since
ADE can occur through a number of mechanisms and is
not completely understood, clinical trials of vaccine
against SARS-CoV should be conducted with caution.
In summary, SARS neutralizing antibody level is posi-
tively correlated with clinical severity, and in a portion of
the patients with mild infection, a detectable neutralizing
antibody response may not develop. All published clinical
and immunologic data on SARS patients suggest that a
strong cell-mediated Th1 response is causally related to a
severe clinical outcome, whereas high neutralizing anti-
body is probably a concurrent event of a strong Th1 activa-
tion. Early neutralizing antibody responders are more likely
to be older, to have a higher case-fatality rate, and to sur-
vive for a shorter time. These observations, if corroborated
with further analysis of data collected in other countries,
should raise the concerns of possible ADE in the pathogen-
esis of SARS-CoV infection in humans and should be con-
sidered in the process of vaccine development.
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